

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 April 2025 (17.04.2025)



(10) International Publication Number
WO 2025/080592 A1

(51) International Patent Classification:

A61K 31/4709 (2006.01) A61K 31/5377 (2006.01)
A61K 31/4745 (2006.01) A61K 39/00 (2006.01)
A61K 31/506 (2006.01) A61K 45/06 (2006.01)
A61K 31/517 (2006.01) A61P 35/00 (2006.01)
A61K 31/519 (2006.01) A61P 35/02 (2006.01)

(21) International Application Number:

PCT/US2024/050390

(22) International Filing Date:

08 October 2024 (08.10.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/588,922 09 October 2023 (09.10.2023) US
63/678,693 02 August 2024 (02.08.2024) US

(71) Applicant: INCYTE CORPORATION [US/US]; 1801
Augustine Cut-off, Wilmington, Delaware 19803 (US).

(72) Inventors: GALLION, Alexandra; 1801 Augustine Cut-
off, Wilmington, Delaware 19803 (US). KIM, Sunkyu;
1801 Augustine Cut-off, Wilmington, Delaware 19803
(US). ROMAN, Valerie; 1801 Augustine Cut-off, Wilm-


ington, Delaware 19803 (US). SMITH, Amanda; 1801
Augustine Cut-off, Wilmington, Delaware 19803 (US).
WALLOWER, Renee; 1801 Augustine Cut-off, Wilm-
ington, Delaware 19803 (US). WANG, Hui; 1801 Augustine
Cut-off, Wilmington, Delaware 19803 (US). FARREN,
Matthew; 1801 Augustine Cut-off, Wilmington, Delaware
19803 (US).

(74) Agent: TRINQUE, Brian; LATHROP GPM LLP, 28 State
Street, Boston, Massachusetts 02109-1775 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

(54) Title: COMBINATION COMPRISING A KRAS G12D INHIBITOR AND AN EGFR INHIBITOR FOR USE IN THE TREAT-
MENT OF CANCER



Group	Day 32			
	Mean Tumor Volume (mm ³)	% TGI	CR (%)	PR(%)
Group 1- Vehicle, QD	1353.78			
Group 2- Cetuximab 3mg/kg (IP, BIW) **	487.05	64	0/10 (0)	0/10 (0)
Group 3- Compound 1 30mg/kg, QD ***	370.18	73	0/10 (0)	0/10 (0)
Group 4- Compound 1 100mg/kg, QD ****	103.11	92	0/10 (0)	10/10 (100)
Group 5- Compound 1 30mg/kg (PO, QD) + Cetuximab 3mg/kg (IP, BIW) ****, #	73.05	95	3/10 (30)	7/10 (70)
Group 6- Compound 1 100mg/kg (PO,QD) + Cetuximab 3mg/kg (IP,BIW)****, &	13.48	100	10/10 (100)	0/10 (0)

FIG. 1

(57) Abstract: Provided herein are methods of treating cancer by administering a combination therapy comprising a KRAS G12D inhibitor and an EGFR inhibitor.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*